Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06056596 · ClinicalTrials.gov registry record · Early Phase 1
Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
A Early Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT06056596 is a Early Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 2 participants.
The verdict
NCT06056596, a Early Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test whether an oral medication (lamivudine) enters the eye and reduces blood markers of inflammation in people who undergo retinal detachment surgery (pars plana vitrectomy). Participants will take the study medication or placebo, and the researchers will measure blood markers of inflammation before and after surgery. The researchers will also measure the amount of medication in the blood and fluid inside the participant's eye (which is collected during surgery).
Interventions
- DRUG Placebo
- DRUG Lamivudine 300 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2024-09-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06056596
The ClinicalTrials.gov registry entry for NCT06056596 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06056596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06056596 about?
NCT06056596 is a clinical study titled "Lamivudine and Plasma Markers of Inflammation in Retinal Detachment". The goal of this clinical trial is to test whether an oral medication (lamivudine) enters the eye and reduces blood markers of inflammation in people who undergo retinal detachment surgery (pars plana vitrectomy). Participants will take the study medication or placebo, and the researchers will meas...
What is the current status of trial NCT06056596?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2024-01-30. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT06056596?
The interventions under investigation include: Placebo (DRUG), Lamivudine 300 MG (DRUG).
Who is sponsoring clinical trial NCT06056596?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.